Andreas Schneeweiss, MD, on Breast Cancer: Comparing Neoadjuvant Chemotherapy With Paclitaxel, Doxorubicin, and Carboplatin

September 20, 2020 By The ASCO Post Staff

Andreas Schneeweiss, MD, of the Heidelberg University Hospital and German Cancer Research Center, discusses phase III survival data from the GeparOcto trial, which compared the neoadjuvant chemotherapy intense dose-dense EPC (epirubicin, paclitaxel, and cyclophosphamide) with weekly paclitaxel and liposomal doxorubicin (with or without carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer (Abstract 160O).

Related Content